Skip to main content

Table 2 Population characteristics

From: Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues

 

OXFD

IJB95/96

JNIadj

JNImeta

 

(n = 77)

(n = 212)

(n = 139)

(n = 270)

Mean age at diagnosis

    

(years)

64

58.5

64

58

(range)

(40-86)

(31-87)

(46-87)

(26-89)

Menopausal status

    

Premenopausal

/

54

7

95

Postmenopausal

/

135

132

175

UK*

77

23

0

0

Event free survival

DMFS/

DMFS/

RFS/

Progression/

(mean; months)

67

78.7

46

13.4

(range)

(0.26-129)

(0.13-142.27)

(2-129)

(1-70)

Death

    

Yes

/

24

51

179

No

/

188

88

91

Tumor size

    

≤2

31

95

25

/

>2

46

95

81

 

(mean)

3.14

2.29

2.6

 

(range)

(1-7)

(0.15-8)

(1-8)

 

UK*

 

22

33

 

Histological grade

    

1

13 (16.7%)

37 (17.5%)

1 (0.01%)

1 (0.003%)

2

40 (51.2%)

89 (42.5%)

16 (11.5%)

34 (12.6%)

3

13 (16.7%)

83 (39.2%)

77 (55.4%)

154 (57.0%)

UK*

11 (15.4%)

3 (0.01%)

45 (32.3%)

81 (30.0%)

Number of metastasis sites

    

0

50

171

/

/

1

24

20

  

2

3

19

  

≥ 3

0

2

  

Histo. Estrogen Receptor status (>10% or ≥10 fmol/mg$)

    

Positive

77

114

139 $

270 $

Negative

0

62

0 $

0 $

UK*

0

36

0 $

0 $

Histo. Progesterone Receptor status (>10% or = 10 fmol/mg)

    

Positive

/

82

88 $

216 $

Negative

 

90

43 $

46 $

UK*

 

40

8 $

8 $

Histo. Ki-67 status (>15%)

    

Positive

/

64

/

/

Negative

 

98

  

UK*

 

50

  

No Positive Lymph Nodes (at surgery)

    

0

45

115

0

121

1 - 3

28

49

96

117

≥ 4

0

36

43

28

UK*

4

12

0

4

  1. *:UK = Unknown.